2023 Australian guideline for assessing and managing cardiovascular disease risk

• Published in: Medical Journal of Australia
• Main Authors: Nelson, Mark R, Banks, Emily, Brown, Alex, Chow, Clara K, Peiris, David P, Stocks, Nigel P, Davies AO, Rebecca, Raffoul, Natalie, Kalman, Lisa, Bradburn, Emily, Jennings, Garry
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2024
• Subjects: First Nations
• Online Access: http://dx.doi.org/10.5694/mja2.52280; https://onlinelibrary.wiley.com/doi/pdf/10.5694/mja2.52280

Abstract Introduction The 2023 Australian guideline for assessing and managing cardiovascular disease risk provides updated evidence‐based recommendations for the clinical assessment and management of cardiovascular disease (CVD) risk for primary prevention. It includes the new Australian CVD risk calculator (Aus CVD Risk Calculator), based on an equation developed from a large New Zealand cohort study, customised and recalibrated for the Australian population. The new guideline replaces the 2012 guideline that recommended CVD risk assessment using the Framingham risk equation. Main recommendations The new guideline recommends CVD risk assessment in people without known CVD: all people aged 45–79 years, people with diabetes from 35 years, and First Nations people from 30 years. The new Aus CVD Risk Calculator should be used to estimate and categorise CVD risk into low (< 5% risk over five years), intermediate (5% to < 10% risk over five years) or high risk (≥ 10% over five years). The following reclassification factors may be applied to recategorise calculated risk to improve accuracy of risk prediction, particularly in individuals close to a risk threshold: Indigenous status/ethnicity, estimated glomerular filtration rate, urine albumin to creatinine ratio measurements, severe mental illness, coronary artery calcium score and family history of premature CVD. A variety of communication formats is available to communicate CVD risk to help enable shared decision making. Healthy lifestyle modification, including smoking cessation, nutrition, physical activity and limiting alcohol, is encouraged for all individuals. Blood pressure‐lowering and lipid‐modifying pharmacotherapies should be prescribed for high risk and considered for intermediate risk individuals, unless contraindicated or clinically inappropriate. Reassessment of CVD risk should be considered within five years for individuals at low risk and within two years for those with intermediate risk. Reassessment of CVD risk is not recommended for ...